{"created":"2023-05-15T15:03:13.326268+00:00","id":85641,"links":{},"metadata":{"_buckets":{"deposit":"80fbd656-cceb-4c37-b0ea-95f53f2ced6f"},"_deposit":{"created_by":1,"id":"85641","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"85641"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00085641","sets":["1"]},"author_link":["1030940","1030942","1030939","1030936","1030941","1030938","1030937"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"104","bibliographicPageStart":"98","bibliographicVolumeNumber":"35","bibliographic_titles":[{"bibliographic_title":"Skin Cancer"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"諸言：\n本邦における悪性黒色腫の罹患頻度は，人口100 万人あたり1 年間におよそ10～20 人とされる1）。その治療において，外科治療がひとつの柱であることは間違いないが，その転移頻度の高さから，しばしば集学的治療が必要となる2）。転移例あるいは切除不能例に対する治療選択は，新規薬剤の開発に伴い，近年，急速に変化してきている。その代表が免疫チェックポイント阻害薬であろう。今やNational comprehensive cancer network（NCCN）のガイドラインにおいても，免疫チェックポイント阻害薬は，BRAF 阻害薬などの分子標的薬とならび，転移例あるいは切除不能例の一次治療として\n明記されるようになった3）。\n放射線腫瘍医（治療医）の立場からすると，悪性黒色腫は放射線感受性（放射線の効果）が低く，根治的治療として放射線治療が用いられるのは稀で，症状緩和目的・姑息的に治療する疾患である，という認識であった。しかしながら，近年の放射線治療と抗腫瘍免疫応答の研究によって，放射線治療は「単なる局所制御のための治療」から「免疫応答を活性化させるトリガー」としての意義をもつことが明らかになりつつあり，さらには悪性黒色腫の免疫原性の高さと相まって，新たな治療戦略になる可能性が示されている。本稿では，我々の研究成果を紹介しつつ，放射線治療と免疫療法を組み合わせる「免疫放射線治療」の可能性について述べる。","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本皮膚悪性腫瘍学会"}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.5227/skincancer.35.98","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0915-3535","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小此木, 範之"}],"nameIdentifiers":[{"nameIdentifier":"1030936","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐藤, 浩央"}],"nameIdentifiers":[{"nameIdentifier":"1030937","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉本, 由哉"}],"nameIdentifiers":[{"nameIdentifier":"1030938","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鈴木, 義行"}],"nameIdentifiers":[{"nameIdentifier":"1030939","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Noriyuki, Okonogi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1030940","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yuya, Yoshimoto","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1030941","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshiyuki, Suzuki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1030942","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"How do we approach to the difficult-to-treat Japanese case. Combination therapy of Immunotherapy and Radiotherapy （Immuno－radiotherapy）","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"How do we approach to the difficult-to-treat Japanese case. Combination therapy of Immunotherapy and Radiotherapy （Immuno－radiotherapy）"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-02-18"},"publish_date":"2022-02-18","publish_status":"0","recid":"85641","relation_version_is_last":true,"title":["How do we approach to the difficult-to-treat Japanese case. Combination therapy of Immunotherapy and Radiotherapy （Immuno－radiotherapy）"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T17:42:01.787918+00:00"}